|
1
|
What are the key statistics about prostate
cancer? American Cancer Society. http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics.
Accessed April 27, 2014
|
|
2
|
Scher HI, Fizazi K, Saad F, et al:
Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ryan CJ, Smith MR, de Bono JS, et al:
Abiraterone in metastatic prostate cancer without previous
chemotherapy. N Engl J Med. 368:138–148. 2013. View Article : Google Scholar
|
|
4
|
Donahue TR, Tran LM, Hill R, et al:
Integrative survival-based molecular profiling of human pancreatic
cancer. Clin Cancer Res. 18:1352–1363. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martini M, Ciraolo E, Gulluni F and Hirsch
E: Targeting PI3K in cancer: any good news? Front Oncol. 3:1082013.
View Article : Google Scholar
|
|
6
|
Jia S, Liu Z, Zhang S, et al: Essential
roles of PI(3)K-p110beta in cell growth, metabolism and
tumorigenesis. Nature. 454:776–779. 2008.PubMed/NCBI
|
|
7
|
Jiang X, Chen S, Asara JM and Balk SP:
Phosphoinositide 3-kinase pathway activation in phosphate and
tensin homolog (PTEN)-deficient prostate cancer cells is
independent of receptor tyrosine kinases and mediated by the
p110beta and p110delta catalytic subunits. J Biol Chem.
285:14980–14989. 2010. View Article : Google Scholar
|
|
8
|
Drake JM, Graham NA, Lee JK, et al:
Metastatic castration-resistant prostate cancer reveals
intrapatient similarity and interpatient heterogeneity of
therapeutic kinase targets. Proc Natl Acad Sci USA.
110:E4762–E4769. 2013. View Article : Google Scholar
|
|
9
|
Kremer CL, Klein RR, Mendelson J, et al:
Expression of mTOR signaling pathway markers in prostate cancer
progression. Prostate. 66:1203–1212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bitting RL and Armstrong AJ: Targeting the
PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Endocr Relat Cancer. 20:R83–R99. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dibble CC, Asara JM and Manning BD:
Characterization of Rictor phosphorylation sites reveals direct
regulation of mTOR complex 2 by S6K1. Mol Cell Biol. 29:5657–5670.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ellis L, Ku SY, Ramakrishnan S, et al:
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR
pathway inhibition in a Pten defecient model of prostate cancer.
Oncotarget. 4:2225–2236. 2013.PubMed/NCBI
|
|
14
|
Yue S, Li J, Lee SY, et al: Cholesteryl
ester accumulation induced by PTEN loss and PI3K/AKT activation
underlies human prostate cancer aggressiveness. Cell Metab.
19:393–406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Muniyan S, Ingersoll MA, Batra SK and Lin
MF: Cellular prostatic acid phosphatase, a PTEN-functional
homologue in prostate epithelia, functions as a prostate-specific
tumor suppressor. Biochim Biophys Acta. pii: S0304-419X(14)00042-0.
Apr 18–2014.(Epub ahead of print). View Article : Google Scholar
|
|
16
|
Hodgson MC, Shao LJ, Frolov A, et al:
Decreased expression and androgen regulation of the tumor
suppressor gene INPP4B in prostate cancer. Cancer Res. 71:572–582.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carver BS, Chapinski C, Wongvipat J, et
al: Reciprocal feedback regulation of PI3K and androgen receptor
signaling in PTEN-deficient prostate cancer. Cancer Cell.
19:575–586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Phin S, Moore MW and Cotter PD: Genomic
rearrangements of in prostate cancer. Front Oncol. 3:2402013.
View Article : Google Scholar
|
|
19
|
Fata JE, Debnath S, Jenkins EC Jr and
Fournier MV: Nongenomic mechanisms of PTEN regulation. Int J Cell
Biol. 2012:3796852012.PubMed/NCBI
|
|
20
|
Ahmad I, Patel R, Singh LB, et al: HER2
overcomes PTEN (loss)-induced senescence to cause aggressive
prostate cancer. Proc Natl Acad Sci USA. 108:16392–16397. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zu K, Martin NE, Fiorentino M, et al:
Protein expression of PTEN, insulin-like growth factor I receptor
(IGF-IR), and lethal prostate cancer: a prospective study. Cancer
Epidemiol Biomarkers Prev. 22:1984–1993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nacerddine K, Beaudry JB, Ginjala V, et
al: Akt-mediated phosphorylation of Bmi1 modulates its oncogenic
potential, E3 ligase activity, and DNA damage repair activity in
mouse prostate cancer. J Clin Invest. 122:1920–1932. 2012.
View Article : Google Scholar
|
|
23
|
Dubrovska A, Kim S, Salamone RJ, et al:
The role of PTEN/Akt/PI3K signaling in the maintenance and
viability of prostate cancer stem-like cell populations. Proc Natl
Acad Sci USA. 106:268–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang S, Gao J, Lei Q, et al:
Prostate-specific deletion of the murine Pten tumor suppressor gene
leads to metastatic prostate cancer. Cancer Cell. 4:209–221. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blando J, Portis M, Benavides F, et al:
PTEN deficiency is fully penetrant for prostate adenocarcinoma in
C57BL/6 mice via mTOR-dependent growth. Am J Pathol. 174:1869–1879.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mulholland DJ, Tran LM, Li Y, et al: Cell
autonomous role of PTEN in regulating castration-resistant prostate
cancer growth. Cancer Cell. 19:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xin L, Teitell MA, Lawson DA, Kwon A,
Mellinghoff IK and Witte ON: Progression of prostate cancer by
synergy of AKT with genotropic and nongenotropic actions of the
androgen receptor. Proc Natl Acad Sci USA. 103:7789–7794. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baca Sylvan C, Prandi D, Lawrence Michael
S, et al: Punctuated evolution of prostate cancer genomes. Cell.
153:666–677. 2013.PubMed/NCBI
|
|
29
|
Nguyen AH, Tremblay M, Haigh K, et al:
Gata3 antagonizes cancer progression in Pten-deficient prostates.
Hum Mol Genet. 22:2400–2410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ai J, Pascal LE, O’Malley KJ, et al:
Concomitant loss of EAF2/U19 and Pten synergistically promotes
prostate carcinogenesis in the mouse model. Oncogene. 33:2286–2294.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thomsen MK, Ambroisine L, Wynn S, et al:
SOX9 elevation in the prostate promotes proliferation and
cooperates with PTEN loss to drive tumor formation. Cancer Res.
70:979–987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim MJ, Cardiff RD, Desai N, et al:
Cooperativity of Nkx3.1 and Pten loss of function in a mouse model
of prostate carcinogenesis. Proc Natl Acad Sci USA. 99:2884–2889.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song H, Zhang B, Watson MA, Humphrey PA,
Lim H and Milbrandt J: Loss of Nkx3.1 leads to the activation of
discrete downstream target genes during prostate tumorigenesis.
Oncogene. 28:3307–3319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen Z, Trotman LC, Shaffer D, et al:
Crucial role of p53-dependent cellular senescence in suppression of
Pten-deficient tumorigenesis. Nature. 436:725–730. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Blando JM, Carbajal S, Abel E, et al:
Cooperation between Stat3 and Akt signaling leads to prostate tumor
development in transgenic mice. Neoplasia. 13:254–265.
2011.PubMed/NCBI
|
|
36
|
Ding Z, Wu CJ, Chu GC, et al:
SMAD4-dependent barrier constrains prostate cancer growth and
metastatic progression. Nature. 470:269–273. 2011. View Article : Google Scholar
|
|
37
|
Wang J, Kobayashi T, Floc’h N, et al:
B-Raf activation cooperates with PTEN loss to drive c-Myc
expression in advanced prostate cancer. Cancer Res. 72:4765–4776.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Thomas C, Lamoureux F, Crafter C, et al:
Synergistic targeting of PI3K/AKT pathway and androgen receptor
axis significantly delays castration-resistant prostate cancer
progression in vivo. Mol Cancer Ther. 12:2342–2355. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Kreisberg JI and Ghosh PM:
Cross-talk between the androgen receptor and the
phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr
Cancer Drug Targets. 7:591–604. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kaarbo M, Mikkelsen OL, Malerod L, et al:
PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling
in prostate cancer cells. Cell Oncol. 32:11–27. 2010.PubMed/NCBI
|
|
41
|
Chandarlapaty S, Sawai A, Scaltriti M, et
al: AKT inhibition relieves feedback suppression of receptor
tyrosine kinase expression and activity. Cancer Cell. 19:58–71.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wen Y, Hu MCT, Makino K, et al: HER-2/neu
promotes androgen-independent survival and growth of prostate
cancer cells through the Akt pathway. Cancer Res. 60:6841–6845.
2000.PubMed/NCBI
|
|
43
|
Manin M, Baron S, Goossens K, et al:
Androgen receptor expression is regulated by the phosphoinositide
3-kinase/Akt pathway in normal and tumoral epithelial cells.
Biochem J. 366:729–736. 2002.PubMed/NCBI
|
|
44
|
Nan B, Snabboon T, Unni E, X-J Y, Whang Y
and Marcelli M: The PTEN tumor suppressor is a negative modulator
of androgen receptor transcriptional activity. J Mol Endocrinol.
31:169–183. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schwartz S, Carver B, Wongvipat J, et al:
The antitumor effects of PI3K beta inhibitors in PTEN negative
prostate cancer are enhanced by inhibition of reactivated PI3K
alpha signaling. In: Proc 105th Annual Meeting Amer Assoc Cancer
Res; abs. 4774. 2014
|
|
46
|
Toren P, Kim S, Gleave M and Zoubeidi A:
Combined targeting of PI3K/Akt and AR pathway with AZD5363 and
enzalutamide induces anticancer activity in preclinical models of
prostate cancer. J Urol. 189(Suppl l4): e4032013. View Article : Google Scholar
|
|
47
|
Taylor BS, Schultz N, Hieronymus H, et al:
Integrative genomic profiling of human prostate cancer. Cancer
Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Attard G, Swennenhuis JF, Olmos D, et al:
Characterization of ERG, AR and PTEN gene status in circulating
tumor cells from patients with castration-resistant prostate
cancer. Cancer Res. 69:2912–2918. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jendrossek V, Henkel M, Hennenlotter J, et
al: Analysis of complex protein kinase B signalling pathways in
human prostate cancer samples. BJU Int. 102:371–382. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jia S, Gao X, Lee SH, et al: Opposing
effects of androgen deprivation and targeted therapy on prostate
cancer prevention. Cancer Discov. 3:44–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sircar K, Yoshimoto M, Monzon FA, et al:
PTEN genomic deletion is associated with p-Akt and AR signalling in
poorer outcome, hormone refractory prostate cancer. J Pathol.
218:505–513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Schmidt H, DeAngelis G, Eltze E, Gockel I,
Semjonow A and Brandt B: Asynchronous growth of prostate cancer is
reflected by circulating tumor cells delivered from distinct, even
small foci, harboring loss of heterozygosity of the PTEN gene.
Cancer Res. 66:8959–8965. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Janku F, Tsimberidou AM, Garrido-Laguna I,
et al: PIK3CA mutations in patients with advanced cancers treated
with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 10:558–565.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
McMenamin ME, Soung P, Perera S, Kaplan I,
Loda M and Sellers WR: Loss of PTEN expression in paraffin-embedded
primary prostate cancer correlates with high Gleason score and
advanced stage. Cancer Res. 59:4291–4296. 1999.PubMed/NCBI
|
|
55
|
Dreher T, Zentgraf H, Abel U, et al:
Reduction of PTEN and p27kip1 expression correlates with tumor
grade in prostate cancer. Analysis in radical prostatectomy
specimens and needle biopsies. Virchows Arch. 444:509–517. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Schmitz M, Grignard G, Margue C, et al:
Complete loss of PTEN expression as a possible early prognostic
marker for prostate cancer metastasis. Int J Cancer. 120:1284–1292.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Koumakpayi IH, Le Page C, Mes-Masson AM
and Saad F: Hierarchical clustering of immunohistochemical analysis
of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and
prognostic significance in prostate cancer. Br J Cancer.
102:1163–1173. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Malik SN, Brattain M, Ghosh PM, et al:
Immunohistochemical demonstration of phospho-Akt in high Gleason
grade prostate cancer. Clin Cancer Res. 8:1168–1171.
2002.PubMed/NCBI
|
|
59
|
Hammarsten P, Cipriano M, Josefsson A, et
al: Phospho-Akt immunoreactivity in prostate cancer: relationship
to disease severity and outcome, Ki67 and phosphorylated EGFR
expression. PLoS One. 7:e479942012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
McCall P, Gemmell LK, Mukherjee R,
Bartlett JM and Edwards J: Phosphorylation of the androgen receptor
is associated with reduced survival in hormone-refractory prostate
cancer patients. Br J Cancer. 98:1094–1101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Bedolla R, Prihoda TJ, Kreisberg JI, et
al: Determining risk of biochemical recurrence in prostate cancer
by immunohistochemical detection of PTEN expression and Akt
activation. Clin Cancer Res. 13:3860–3867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Won JR, Gao D, Chow C, et al: A survey of
immunohistochemical biomarkers for basal-like breast cancer against
a gene expression profile gold standard. Mod Pathol. 26:1438–1450.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Van de Sande T, Roskams T, Lerut E, et al:
High-level expression of fatty acid synthase in human prostate
cancer tissues is linked to activation and nuclear localization of
Akt/PKB. J Pathol. 206:214–219. 2005.PubMed/NCBI
|
|
64
|
Templeton AJ, Dutoit V, Cathomas R, et al:
Phase 2 trial of single-agent everolimus in chemotherapy-naive
patients with castration-resistant prostate cancer (SAKK 08/08).
Eur Urol. 64:150–158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wagle N, Grabiner BC, Van Allen EM, et al:
Activating mTOR mutations in a patient with an extraordinary
response on a phase I trial of everolimus and pazopanib. Cancer
Discov. 4:546–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Banerji U: Results of two phase 1
multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3:
biomarker and early clinical evaluation in Western and Japanese
patients with advanced solid tumors. In: 2013, Proc Annual Meeting
Amer Assoc Cancer Res (abstract LB-66); 2013;
|
|
67
|
Chee KG, Longmate J, Quinn DI, et al: The
AKT inhibitor perifosine in biochemically recurrent prostate
cancer: a phase II California/Pittsburgh cancer consortium trial.
Clin Genitourin Cancer. 5:433–437. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Posadas EM, Gulley J, Arlen PM, et al: A
phase II study of perifosine in androgen independent prostate
cancer. Cancer Biol Ther. 4:1133–1137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Bendell JC, Ervin TE, Senzer N, et al:
Results of the X-PECT study: a phase III randomized double-blind,
placebo-controlled study of perifosine plus capecitabine (P-CAP)
versus placebo plus capecitabine (CAP) in patients (pts) with
refractory metastatic colorectal cancer (mCRC). J Clin Oncol.
30:LBA35012012.
|
|
70
|
Busaidy NL, Farooki A, Dowlati A, et al:
Management of metabolic effects associated with anticancer agents
targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 30:2919–2928.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Bendell JC, Rodon J, Burris HA, et al:
Phase I dose-escalation and -expansion study of buparlisib
(BKM120), an oral pan-class I PI3K inhibitor, in patients with
advanced solid tumors. J Clin Oncol. 30:282–290. 2012. View Article : Google Scholar
|
|
72
|
Amato RJ, Wilding G, Bubley G, Loewy J,
Haluska F and Gross ME: Safety and preliminary efficacy analysis of
the mTOR inhibitor ridaforolimus in patients with taxane-treated,
castration-resistant prostate cancer. Clin Genitourin Cancer.
10:232–238. 2012. View Article : Google Scholar
|
|
73
|
Hsieh AC, Liu Y, Edlind MP, et al: The
translational landscape of mTOR signalling steers cancer initiation
and metastasis. Nature. 485:55–61. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mateo J, Schoffski P, Olmos D, et al:
Abstract B187: Pharmacodynamics of OSI-027, a dual mTORC1/mTORC2
inhibitor, in tumor and surrogate tissues: Results from the
expansion phase of a first-in-man study. Mol Cancer Ther.
12:B1872013. View Article : Google Scholar
|
|
75
|
Baselga J, Campone M, Piccart M, et al:
Everolimus in post-menopausal hormone-receptor-positive advanced
breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Floc’h N, Kinkade CW, Kobayashi T, et al:
Dual targeting of the Akt/mTOR signaling pathway inhibits
castration-resistant prostate cancer in a genetically engineered
mouse model. Cancer Res. 72:4483–4493. 2012.PubMed/NCBI
|
|
77
|
Squillace RM, Miller D, Wardwell SD, Wang
F, Clackson T and Rivera VM: Synergistic activity of the mTOR
inhibitor ridaforolimus and the antiandrogen bicalutamide in
prostate cancer models. Int J Oncol. 41:425–432. 2012.PubMed/NCBI
|
|
78
|
Nakabayashi M, Werner L, Courtney KD, et
al: Phase II trial of RAD001 and bicalutamide for
castration-resistant prostate cancer. BJU Int. 110:1729–1735. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Pan C, Robles D, D’Abronzo L, et al:
Synergistic effects of everolimus and bicalutamide in
castration-resistant prostate cancer: results from a phase I/II
clinical trial. Cancer Res. 72:57502012. View Article : Google Scholar
|
|
80
|
Patnaik A, Loda M, Kung J, et al: A phase
Ib study of BKM120 combined with abiraterone acetate for
castrate-resistant, metastatic prostate cancer. In: Proc 105th
Annual Meeting Amer Assoc Cancer Res; abs. CT418. 2014
|
|
81
|
Janne PA, Cohen RB, Laird AD, et al: Phase
I safety and pharmacokinetic study of the PI3K/mTOR inhibitor
SAR245409 (XL765) in combination with erlotinib in patients with
advanced solid tumors. J Thorac Oncol. 9:316–323. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Meulenbeld HJ, de Bono JS, Tagawa ST, et
al: Tolerability, safety and pharmacokinetics of ridaforolimus in
combination with bicalutamide in patients with asymptomatic,
metastatic castration-resistant prostate cancer (CRPC). Cancer
Chemother Pharmacol. 72:909–916. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Baiz D, Hassan S, Choi YA, et al:
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted
immunotoxin accelerates apoptosis and regression of prostate
cancer. Neoplasia. 15:1172–1183. 2013.PubMed/NCBI
|
|
84
|
Yasumizu Y, Miyajima A, Kosaka T, Miyazaki
Y, Kikuchi E and Oya M: Dual PI3K/mTOR inhibitor NVP-BEZ235
sensitizes docetaxel in castration resistant prostate cancer. J
Urol. 191:227–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Lamoureux F, Thomas C, Crafter C, et al:
Blocked autophagy using lysosomotropic agents sensitizes resistant
prostate tumor cells to the novel Akt inhibitor AZD5363. Clin
Cancer Res. 19:833–844. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Cen B, Mahajan S, Wang W and Kraft AS:
Elevation of receptor tyrosine kinases by small molecule AKT
inhibitors in prostate cancer is mediated by Pim-1. Cancer Res.
73:3402–3411. 2013. View Article : Google Scholar
|
|
87
|
Kinkade CW, Castillo-Martin M, Puzio-Kuter
A, et al: Targeting AKT/mTOR and ERK MAPK signaling inhibits
hormone-refractory prostate cancer in a preclinical mouse model. J
Clin Invest. 118:3051–3064. 2008.PubMed/NCBI
|
|
88
|
Tai S, Sun Y, Liu N, et al: Combination of
Rad001 (everolimus) and propachlor synergistically induces
apoptosis through enhanced autophagy in prostate cancer cells. Mol
Cancer Ther. 11:1320–1331. 2012. View Article : Google Scholar
|
|
89
|
Festuccia C, Gravina GL, Muzi P, et al:
Akt down-modulation induces apoptosis of human prostate cancer
cells and synergizes with EGFR tyrosine kinase inhibitors.
Prostate. 68:965–974. 2008. View Article : Google Scholar : PubMed/NCBI
|
